Slingsby Brian Taylor

Director Brian Taylor Slingsby sold 1,000,000 shares of MLYS for $43,350,000 on 2025-11-20; holds 7,903,838 post-trade.

Director Brian Taylor Slingsby executed a substantial sale of 1,000,000 shares at $43.35, reducing his position by 11.2% while generating $43,350,000 in proceeds. The sale occurred near the company's 52-week high ($47.33), with the stock down only 0.4% over the past 30 days but up 181.3% over 90 days, suggesting a recent appreciation period. Mineralys remains unprofitable with a negative full-year net income of $-36,932,000, which provides important context for director-level equity reduction. His prior open-market sell at MLYS on 2024-07-24 exhibited poor 90-day timing (the stock rose 6.9% afterward), and his cross-ticker sell track record shows a 0.00% well-timed rate, indicating his historical sales have not consistently preceded stock declines.

Director Brian Taylor Slingsby purchased 259,259 shares of MLYS at $13.50 for $3,499,996.50 amid 90-day gain of 33.8%.

Director Brian Taylor Slingsby purchased 259,259 shares of Mineralys Therapeutics at $13.50 on March 13, 2025, increasing his holdings to 8,903,838 shares and committing $3,499,996.50 to the open-market transaction. The purchase occurs against mixed recent price momentum: the stock is -20.9% from its 52-week high of $16.87, down 17.4% over 30 days, yet up 33.8% over the prior 90 days, suggesting the director acquired into a pullback within a recent recovery period. The company remains unprofitable with a negative net income of $-56,342,000.00 over its most recent fiscal year, which combined with the stock's volatility warrants investor scrutiny of the timing and rationale behind this material open-market addition to an already substantial insider position.

Director Brian Taylor sold 550,000 shares at $13.05 ($7.2M), reducing holdings by 6.0% of unprofitable biotech company.

Director Slingsby Brian Taylor sold 550,000 shares at $13.05 on 2024-07-24, reducing his stake from 9,194,579 to 8,644,579 shares. The company posted net income of $-31,508,000 over its most recent full fiscal year, indicating ongoing cash burn typical of early-stage biotech. The sale occurred at $13.05 while the current price is $13.45, suggesting the transaction executed slightly below recent market levels. Taylor retains substantial holdings of 8,644,579 shares post-transaction, indicating continued exposure to the company despite the sale.